PubRank

Patrick Most

Author PubWeight™ 41.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008 2.22
2 Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007 1.73
3 S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011 1.68
4 Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011 1.54
5 VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. Genes Dev 2005 1.53
6 Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 2010 1.52
7 Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation 2012 1.52
8 Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol 2006 1.40
9 Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer 2010 1.38
10 AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2012 1.35
11 Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2004 1.32
12 Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol 2010 1.32
13 Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail 2007 1.27
14 Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007 1.16
15 S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol 2009 1.13
16 S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2006 1.07
17 Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 2008 1.01
18 The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002 1.01
19 S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 2005 1.01
20 Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci 2008 1.00
21 S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res 2010 0.96
22 Heart failure gene therapy: the path to clinical practice. Circ Res 2013 0.95
23 S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med 2004 0.91
24 S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function. J Biomed Biotechnol 2010 0.89
25 BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells. Clin Transl Sci 2008 0.89
26 S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials. J Mol Cell Cardiol 2010 0.87
27 S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol 2007 0.86
28 Orai1 deficiency leads to heart failure and skeletal myopathy in zebrafish. J Cell Sci 2012 0.86
29 Sealing the leak, healing the heart. Nat Med 2003 0.84
30 Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J Mol Med (Berl) 2009 0.81
31 MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. PLoS One 2013 0.81
32 S100 proteins: a missing piece in the puzzle of heart failure? Cardiovasc Res 2007 0.80
33 IL-1α reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy? Am J Respir Cell Mol Biol 2014 0.80
34 Inhibition of angiotensin II Gq signaling augments beta-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure. J Mol Cell Cardiol 2008 0.79
35 Cardiac calcium handling on trial: targeting the failing cardiomyocyte signalosome. Circ Res 2014 0.77
36 Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment. Pharmacogenomics 2011 0.76
37 Conditional AC type VI expression in the heart: relevant insights into function of inducible target gene expression. Cardiovasc Res 2002 0.76
38 Erratum: Myoscape controls cardiac calcium cycling and contractility via regulation of L-type calcium channel surface expression. Nat Commun 2016 0.75
39 Recent findings into the potential of gene therapy to reverse heart failure. Expert Opin Biol Ther 2007 0.75